Compare ELS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELS | GH |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 13.3B |
| IPO Year | 1994 | 2018 |
| Metric | ELS | GH |
|---|---|---|
| Price | $67.11 | $106.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 22 |
| Target Price | $70.50 | ★ $103.59 |
| AVG Volume (30 Days) | ★ 1.8M | 1.8M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | 2.55 | ★ 6.74 |
| EPS | ★ 2.01 | N/A |
| Revenue | ★ $1,531,382,000.00 | $982,021,000.00 |
| Revenue This Year | $3.71 | $35.29 |
| Revenue Next Year | $1.38 | $27.42 |
| P/E Ratio | $33.35 | ★ N/A |
| Revenue Growth | 0.34 | ★ 32.88 |
| 52 Week Low | $57.63 | $34.91 |
| 52 Week High | $70.24 | $120.74 |
| Indicator | ELS | GH |
|---|---|---|
| Relative Strength Index (RSI) | 65.00 | 49.95 |
| Support Level | $66.76 | $102.00 |
| Resistance Level | $68.54 | $110.46 |
| Average True Range (ATR) | 1.27 | 6.19 |
| MACD | 0.18 | -0.33 |
| Stochastic Oscillator | 75.89 | 46.62 |
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 455 properties across the US with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.